寻求合作
[供] 一家荷兰-英国的合资企业可提供人体免疫系统分析的测试技术
合作类型:技术     行业类别: 生物科学与健康     国家:荷兰
发布时间:2017年06月14日     过期时间:2020年03月10日     点击数:25

一家荷兰-英国的合资企业正在开发一种生物和分析测定系统,该系统可将新型细胞系,3D支架和原代细胞结合在一起,可为人类提供免疫系统分析,模拟体内人类微环境。 该公司拟通过研究合作协议的形式与感兴趣的合作伙伴进行合作,以帮助验证该系统。 此外,该企业还可为其在工业环境中的发展和应用提供咨询和指导。

 

A Dutch-British joint venture is developing a system of biological and analytical assays that combines novel cell lines, 3D scaffolds and primary cells to deliver an in vitro human cell-based immune system that mimics the in vivo human microenvironment. The company aims at a research cooperation agreement and further collaboration to help validate the system. Furthermore, advice and guidance on the development and application of the system in an industrial setting is wanted.

 

 

Description

 

A Dutch-British company is specialized in biological and analytical preclinical testing of novel drugs and  recently developed a novel in vitro testing platform. 

The introduction of novel drugs, based on new molecular insight, can be recognized as most promising for our healthcare for the coming decades. They are target specific, can be applied as personalized medicine and can be very effective in contrast to generic medicines. However in order to bring these new compounds to the market as new and registered medicines, extensive clinical trials have to be performed. These trials are very time consuming and costly.

The offered  in vitro platform is of strategic great value, since it is able to predict the behaviour and noxiousness of potential drugs in the preclinical testing phase of development. The new testing platform  makes the whole route of drug development faster and economically feasible and  is therefore highly encouraged by regulatory authorities. The need for improved and more rapid and economical trials is urgent since, due to the success of modern molecular biology, more and better solutions and drug targets will be discovered. It is here that the offered platform may claim great impact.

Crucial to the adoption of the offered platform will be to show proof of principle with relevant drug molecules. The company is seeking (bio)pharmaceutical partners (e.g. drug discovery groups, contract research organisations and biosimilars groups) able to provide compounds to validate their model as well as to help validate the offered in vitro system. Ideally this would include marketed compounds and molecules (with associated data) that failed due to immunogenicity. 

 

The company aims at a research cooperation agreement and is open to discuss also other types of agreements. Furthermore, the company is also seeking advice and guidance on the development and application of the testing platform in an industrial setting.

 

Type and Role of Partner Sought

 

Industry and academia and actors in the fields of (bio)pharmaceutical development  (e.g. drug discovery groups, contract research organisations and biosimilars groups).

A concerted research effort and further business development is needed and is based on the open innovation methodology, bringing together collective intelligence of various industries, companies and knowledge organizations.

【供】170163 TONL20170201001

回复列表
1 / 共0页


发表回复:
请在下面登录后,才能发表回复
会员帐号: 密码: